Skip to search formSkip to main contentSkip to account menu

cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine

Known as: Rituximab/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine, R-CHOP Regimen, Rituxan/CHOP 
An abbreviation for a chemotherapy combination that is used to treat non-Hodgkin lymphoma and mantle cell lymphoma and is being studied in the… 
National Institutes of Health

Related topics

Related topics

8 relations
CyclophosphamideDoxorubicinDoxorubicin HydrochlorideLymphoma, Non-Hodgkin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
Abstract Tumor-associated macrophages (TAMs) and regulatory T-cells (Tregs) play an important role in the tumor microenvironment… 
Highly Cited
2014
Highly Cited
2014
Chemotherapy‐induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with “resolved” HBV infection (hepatitis B surface antigen [HBsAg… 
Highly Cited
2014
Highly Cited
2014
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease
Abstract The optimal therapy for primary mediastinal B-cell lymphoma is a subject of ongoing debate, with no accepted standard of… 
Highly Cited
2013
Highly Cited
2013
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from…
Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal center B-cell (GCB)-like and… 
Highly Cited
2013
Highly Cited
2013
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and confer an increased risk to cyclophosphamide… 
Review
2012
Review
2012
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.
Role of interim-PET (I-PET) in diffuse large B-cell Lymphoma (DLBCL) is controversial. To determine predictive value of I-PET on… 
Highly Cited
2010
Highly Cited
2010
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
The survival of diffuse large B-cell lymphoma patients varies considerably, reflecting the molecular diversity of tumors. In view… 
Highly Cited
2009
Highly Cited
2009
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
Approximately 5% to 10% of diffuse large B-cell lymphomas (DLBCLs) harbor an MYC oncogene rearrangement (MYC+). The prognostic… 
Review
2006
Review
2006
Intravascular lymphoma: the oncologist's "great imitator".
Intravascular lymphoma (IVL) is a rare subtype of extranodal diffuse large B-cell lymphoma with a distinct presentation… 
Highly Cited
2004
Highly Cited
2004
Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
PURPOSE Long-term follow-up with updated time to disease progression (TTP) and duration of response (DR) data are presented from… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)